View the Encompass marketing brochure here
About Encompass Compliance
Comprehensive provider of workplace drug, alcohol & marijuana compliance services. Providing organizations with policies, procedures and training for supervisors and employees to manage their programs. In addition Encompass provides claim defense services for employer safety, risk and legal teams as well as information and content that supports the Human Resource and Drug Compliance Program Managers.
Contact Encompass Compliance today at 866-328-7487 for more information about how they can assist you and your organization.
Richard Sharp - CEO
Mr. Sharp is CEO and Chairman of the board, was the co-founder and CEO of FightReady, LLC. He is responsible for the creation and go to market strategy providing compliance and training solutions to Insurance Carriers and Insured organizations throughout the United States. These services assisted with reducing costs on Worker's Compensation claims, wrongful terminations and other employee lifecycle issues
James Schoonover - COO
After a 16 year career with MEDTOX Scientific, which was sold to Laboratory Corporation of America in 2012. Schoonover has been involved in the drug and alcohol testing industry since 1987, having held both operating and marketing positions with companies involved in laboratory testing and specimen collection services. "His public company experience will help Encompass, as we bring our new web-based compliance platform to market. I believe Jim will offer a fresh perspective and heightened communication capabilities to our valued shareholders.", stated Richard Sharp CEO of ENCC. Mr. Schoonover has an undergraduate degree from Cornell University in Ithaca, NY and an MBA from the University of St. Thomas in Minneapolis, MN.
Nick Hartman - VP Channel Partners and Alliances
Nick is very well networked thought leader and a recognized industry subject matter expert. He built an occupational health product & services division from scratch, with a SaaS company that emerged from a startup into an industry leader. Nick has consulted, implemented and managed drug-free workplace programs for 1000's of employers across the US and across the world.
ENCC Share Structure (updated June 22, 2016)
|Market Value1 ||$1,947,703 ||a/o Aug 17, 2016 || |
|Shares Outstanding ||85,425,560 ||a/o Aug 15, 2016 || +17mm a/o Jun 2016 |
|*Float ||12,708,942 ||a/o Aug 15, 2016 || |
|Authorized Shares ||125,000,000 ||a/o Aug 15, 2016 || |
*This Float is an estimate only based on the report issued Feb 20th, stating that Both Directors hold 21,500,000 shares (total 43mm, deducted f rom the stated Outstanding of 61.9mm equates to appx 25mm) There was no mention of other restricted shares but if further reports stat anything of the like, it will be updated as soon as possible here in the iBox. Please do your own Due Diligance and any suggestions/corrections/updates etc. please post them on the board. *Source OTCmarkets.com
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995. Statements about the company's future expectations including future revenues and earnings, and all other statements on this site other than historical facts are "forward- looking statements" within the meaning of section 27A of the securities act of 1933, section 21e of the Securities Exchange Act of 1934, and as that term is defined in the private securities litigation reform act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change any time, and the company's actual results could differ materially from expected results. The company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Neither the information nor any opinion which may be expressed or implied constitutes a solicitation for the purchase or sale of any securities referred to herein. The company advises all readers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this document. None of the material on this site shall be construed as any kind of investment advice.